Ticker Symbol: LPTX
Leap Therapeutics Inc
$2.40 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001509745
Company Profile
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 47 Thorndike St Ste B1-1
Website: www.leaptx.com
CEO: N/A
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 13, 2023 03:00 PM EST
Previous Close: $1.52
Change:
$0.07
(
4.83%)
Days Range: $1.45 - $1.56
Beta: 1.10
52wk. High: $10.19
52wk. Low: $1.24
Ytd. Change -61.39%
50 Day Moving Average: $1.57
200 Day Moving Average: $3.43
Shares Outstanding: 25565414
Valuation
Market Cap: 3.9B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A